People with the APOE e4 gene variant who are at an increased risk for Alzheimer's disease but who are also heterozygous for a Klotho haplotype may have a reduced disease risk, a new study has found.
Gladstone Institutes researchers will use proteomic, genomic, and gene-altering approaches to investigate apoe4 toxicity as part of a five-year project.
Using exome data from Alzheimer's disease cases and controls with or without the APOE4 risk allele, investigators identified potential risk-stratifying variants.
By combining iPSCs, CRISPR gene editing, and transcriptomic approaches, researchers examined the effects of an Alzheimer's disease risk variant on brain cells.
The model aims to uncover stroke patients at high, medium, or low risk of cerebral amyloid angiopathy, which is linked to additional strokes or dementia.
Researchers sequenced the APOE gene in over 900 individuals, finding supporting evidence for the APOE2 allele's role in longevity and lower levels of lipids.
A team led by Buck Institute for Research on Aging scientists has reported that ApoE4 binds the promoter regions of Alzheimer's disease genes, including SirT1.
The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.
